

Generics for Long-Acting Injectables: Building a Pathway to Success

Robert Lionberger

Director

Office of Research and Standards

Office of Generic Drugs

Controlled Release Society Annual Meeting

July 1, 2020

Why are Generics for Long-Acting Injectables (LAI) Complicated?

- •An in vivo release controlling mechanism that needs to work for months
 - Limited predictive in vitro methods for product development
- Pharmacokinetic bioequivalence studies often need patients and take months to years
- •Importance of understanding and characterizing the polymeric materials

FDA




GDUFA Tools for Generic LAI

• Problem

- Limited generic competition in the LAI space
- Solution
 - GDUFA support for scientific tools
 - Research program
 - GDUFA support for regulatory tools
 - Product specific guidance, pre-ANDA meetings

GDUFA: Generic Drug User Fee Amendments Commitment letter: <u>https://www.fda.gov/media/101052/download</u> Product Specific Guidance for Generic Drug Development: <u>https://www.accessdata.fda.gov/scripts/cder/psg/</u> Pre-ANDA (abbreviated new drug application) meeting guidance: <u>https://www.fda.gov/media/107626/download</u>

Office of Research and Standards Operational Model



The Office of Research and Standards (ORS) is a multidisciplinary Office that plans

www.fda.gov and conducts Research and translates the results into generic drug Standards 4





GDUFA Research Investment in LAI

- •Research began in 2013
 - Focus: in vitro to in vivo correlations
 - Focus: polymer characterization
 - Focus: modeling and simulation for both the formulation and pharmacokinetic studies
- •FDA staff and many of our collaborators will be speaking today



Research Outcomes

- •See GDUFA research reports on LAI
 - <u>https://www.fda.gov/drugs/generic-drugs/generic-drugs-guidances-reports</u>
- More than 20 publications
- More than 80 posters/presentations at scientific meetings
- •12 Product Specific Guidances for LAI
- •24 pre-ANDA meetings on LAI

Keys to Success for Complex Generics

- Why is the reference product (RLD) complex?
- What is the scientific and regulatory landscape
 - Guidances and Citizen Petitions
- Pay attention to the science
- Use the pre-ANDA program
- Monitor changes in the RLD and the regulatory landscape during ANDA review
 - Be mindful of standard "simpler" issues such as Q1Q2 that impact ANDA development

FD A

